臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c h"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 56-80 / 1656 (共67页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2022-08-19T00:21:15Z	Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract	Cheng A.-L.; Wu C.-Y.; Chen J.-S.; Li C.-C.; Liu H.-T.; Hsu C.-H.; Lu Y.-S.; Yeh K.-H.; Yang C.-H.; Shen Y.-C.; CHIUN HSU
臺大學術典藏	2022-08-19T00:21:12Z	Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer	Shiah H.-S.; Cheng A.-L.; CHIUN HSU; Hsu C.-H.; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T.
臺大學術典藏	2022-08-19T00:21:10Z	A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer	Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; CHIUN HSU; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H.
臺大學術典藏	2022-08-19T00:21:09Z	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma	Lin C.-C.; Yeh K.-H.; Yang C.-H.; CHIUN HSU; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2022-08-19T00:21:08Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Lin Z.-Z.; CHIUN HSU; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏	2022-08-19T00:21:05Z	Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway	Chen K.-F.; Yeh P.-Y.; CHIUN HSU; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L.
臺大學術典藏	2022-08-19T00:21:03Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Cheng A.-L.; Ding Y.-H.; CHIUN HSU; Shao Y.-Y.; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H.
臺大學術典藏	2022-08-19T00:21:01Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Shao Y.-Y.
臺大學術典藏	2022-08-19T00:21:00Z	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil	Wei S.-Y.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Hsu C.-H.; Hu F.-C.; CHIUN HSU; Yu C.-W.; Shen Y.-C.; Hsu C.-Y.
臺大學術典藏	2022-08-19T00:20:58Z	Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma	Shao Y.-Y.; Lin Z.-Z.; CHIUN HSU; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2022-08-19T00:20:57Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.; Chang D.-Y.; Hu F.-C.; Shao Y.-Y.; CHIUN HSU; Lin Z.-Z.
臺大學術典藏	2022-08-19T00:20:55Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shen Y.-C.; Hsu C.-H.; Cheng A.-L.; CHIUN HSU; Lin Z.-Z.; Lu L.-C.; Shao Y.-Y.
臺大學術典藏	2022-08-19T00:20:51Z	Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size	Lai M.-S.; Yang J.C.-H.; Cheng A.-L.; Hsu C.-H.; Kuo R.N.-C.; Yeh Y.-C.; Shao Y.-Y.; CHIUN HSU; Shau W.-Y.; Lin Z.-Z.
臺大學術典藏	2022-08-19T00:20:44Z	Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy	Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2022-08-19T00:20:42Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	CHIUN HSU; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.; Guo J.-C.; Kuo T.-C.; Wu H.; Yang S.-H.
臺大學術典藏	2022-08-19T00:20:41Z	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma	Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F.
臺大學術典藏	2022-08-19T00:20:40Z	Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy	CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.
臺大學術典藏	2022-08-19T00:20:38Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Liu T.-H.; Shao Y.-Y.; Lu L.-C.
臺大學術典藏	2022-08-19T00:20:36Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; CHIUN HSU; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2022-08-19T00:20:34Z	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO	Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E.
臺大學術典藏	2022-08-19T00:20:33Z	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study	Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W.
臺大學術典藏	2022-08-19T00:20:30Z	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma	Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; CHIUN HSU; Hsu C.-H.; Yang M.-H.; Chao Y.
臺大學術典藏	2022-08-19T00:20:28Z	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma	Hung Y.-P.; CHIUN HSU; Lee J.-M.; Chao Y.; Shao Y.-Y.; Hsu C.-H.; Yang M.-H.
臺大學術典藏	2022-08-19T00:20:28Z	Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma	Sun N.-Y.; CHIUN HSU; Cheng A.-L.; Shao Y.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.-H.; Hsu H.-C.; Lin Z.-Z.
臺大學術典藏	2022-08-19T00:20:27Z	Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials	Lin Z.-Z.; Hsu C.-H.; Liang P.-C.; Chen B.-B.; Shao Y.-Y.; CHIUN HSU; Cheng A.-L.; Shih T.T.-F.

显示项目 56-80 / 1656 (共67页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52908825 在线人数 : 1125 教育部委托研究计画计画执行:国立台湾大学图书馆